<DOC>
	<DOC>NCT01635686</DOC>
	<brief_summary>The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.</brief_summary>
	<brief_title>Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1. Healthy males, 20 to 45 years of age the moment of screening 2. Body mass index is between 19.0 and 27.0 kg/m2 1. Hypersensitivity response to the experimental and comparator drugs 2. The tuberculosis patient or latent tuberculosis patient</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>